Mesenchymal Stromal Cells for Graft-versus-Host Disease: A Trilogy

Affiliations

Jacques Galipeau. Biol Blood Marrow Transplant. 2020 May.

. 2020 May;26(5):e89-e91.

doi: 10.1016/j.bbmt.2020.02.023. Epub 2020 Mar 7.

¹ From the Department of Medicine and Carbone Cancer Center, University of Wisconsin in Madison, Madison, Wisconsin. Electronic address: jgalipeau@wisc.edu.

No abstract available

Conflict of interest statement

Declaration of interests

The author declares no competing interests.

1. Kebriaei P, et al. , A Phase 3 Randomized Study of Remestemcel-L versus Placebo Added to Second-Line Therapy in Patients with Steroid-Refractory Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant, 2019. - PMC - PubMed
1. Kurtzberg J, et al. , Study 275: Updated Expanded Access Program for Remestemcel-L in Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD) in Children. Biol Blood Marrow Transplant, 2020. - PMC - PubMed
1. Kurtzberg J, et al. , A Phase 3, Single-arm, Prospective Study of Remestemcel-L, Ex-vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients who Failed to Respond to Steroid Treatment for Acute GVHD. Biol Blood Marrow Transplant, 2020. - PMC - PubMed
1. Galipeau J and Sensebe L, Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities. Cell Stem Cell, 2018. 22(6): p. 824–833. - PMC - PubMed
1. Ferreira JR, et al. , Mesenchymal Stromal Cell Secretome: Influencing Therapeutic Potential by Cellular Pre-conditioning. Front Immunol, 2018. 9: p. 2837. - PMC - PubMed